Rozanolixizumab

For research use only. Not for therapeutic Use.

  • CAT Number: I044208
  • CAS Number: 1584645-37-3
  • Purity: ≥95%
Inquiry Now

Rozanolixizumab(Cat No.:I044208)is a humanized monoclonal antibody that targets the neonatal Fc receptor (FcRn), blocking its interaction with immunoglobulin G (IgG). By inhibiting FcRn, rozanolixizumab accelerates the degradation of pathogenic IgG antibodies, reducing their serum levels. It is primarily developed for treating IgG-mediated autoimmune diseases such as myasthenia gravis and immune thrombocytopenia (ITP). Administered subcutaneously, rozanolixizumab offers a targeted approach to immunosuppression without broadly affecting the immune system. Its mechanism provides a promising alternative to traditional immunosuppressive therapies, aiming to improve outcomes with fewer systemic side effects.

Request a Quote